Cingulate Inc. Logo

Cingulate Inc.

CING

(1.8)
Stock Price

0,40 USD

-2937.07% ROA

913.19% ROE

-0.82x PER

Market Cap.

6.666.755,00 USD

-3741.3% DER

0% Yield

-4.48% NPM

Cingulate Inc. Stock Analysis

Cingulate Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cingulate Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (1017.14%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0.58x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-137%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

5 ROA

The stock's ROA (-3262.02%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Cingulate Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cingulate Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Cingulate Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cingulate Inc. Revenue
Year Revenue Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cingulate Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 9.094.826
2020 5.093.277 -78.57%
2021 8.410.489 39.44%
2022 8.995.280 6.5%
2023 15.695.408 42.69%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cingulate Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 2.302.000
2020 1.991.000 -15.62%
2021 12.269.000 83.77%
2022 8.506.438 -44.23%
2023 7.303.288 -16.47%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cingulate Inc. EBITDA
Year EBITDA Growth
2019 -11.467.914
2020 -6.418.248 -78.68%
2021 -19.971.172 67.86%
2022 -17.501.718 -14.11%
2023 -45.997.392 61.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cingulate Inc. Gross Profit
Year Gross Profit Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 -22.998.696 100%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cingulate Inc. Net Profit
Year Net Profit Growth
2019 -11.445.336
2020 -7.283.867 -57.13%
2021 -20.740.493 64.88%
2022 -17.850.232 -16.19%
2023 -23.916.216 25.36%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cingulate Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -1
2020 -1 0%
2021 -3 100%
2022 -2 -100%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cingulate Inc. Free Cashflow
Year Free Cashflow Growth
2019 -10.548.424
2020 -7.213.175 -46.24%
2021 -11.247.508 35.87%
2022 -16.036.228 29.86%
2023 -4.291.965 -273.63%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cingulate Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 -9.532.610
2020 -6.811.079 -39.96%
2021 -10.432.772 34.71%
2022 -15.882.808 34.31%
2023 -4.291.965 -270.06%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cingulate Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 1.015.814
2020 402.096 -152.63%
2021 814.736 50.65%
2022 153.420 -431.05%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cingulate Inc. Equity
Year Equity Growth
2019 615.880
2020 1.292.435 52.35%
2021 20.843.542 93.8%
2022 -69.408.496 130.03%
2023 -96.334 -71949.84%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cingulate Inc. Assets
Year Assets Growth
2019 5.280.772
2020 5.787.556 8.76%
2021 22.886.257 74.71%
2022 11.405.057 -100.67%
2023 5.870.258 -94.29%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cingulate Inc. Liabilities
Year Liabilities Growth
2019 4.664.892
2020 4.495.121 -3.78%
2021 2.042.715 -120.06%
2022 7.523.035 72.85%
2023 5.966.592 -26.09%

Cingulate Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
194.77
Net Income per Share
-8.72
Price to Earning Ratio
-0.82x
Price To Sales Ratio
0x
POCF Ratio
-8.43
PFCF Ratio
-0.4
Price to Book Ratio
-1459.92
EV to Sales
0
EV Over EBITDA
-0.32
EV to Operating CashFlow
-0.5
EV to FreeCashFlow
-0.49
Earnings Yield
-1.23
FreeCashFlow Yield
-2.53
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.98
Graham NetNet
-0.18

Income Statement Metrics

Net Income per Share
-8.72
Income Quality
0.79
ROE
9.13
Return On Assets
-29.37
Return On Capital Employed
-190
Net Income per EBT
8.13
EBT Per Ebit
0.81
Ebit per Revenue
-0.01
Effective Tax Rate
-295.2

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.65
Operating Profit Margin
-0.01
Pretax Profit Margin
-0.01
Net Profit Margin
-0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.84
Free CashFlow per Share
-0.85
Capex to Operating CashFlow
0.01
Capex to Revenue
-0
Capex to Depreciation
-0.36
Return on Invested Capital
-1886.31
Return on Tangible Assets
-29.37
Days Sales Outstanding
0
Days Payables Outstanding
0.1
Days of Inventory on Hand
0.05
Receivables Turnover
659697.93
Payables Turnover
3812.25
Inventory Turnover
7158.51
Capex per Share
-0.01

Balance Sheet

Cash per Share
0,10
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
-20.51
Debt to Equity
-37.41
Debt to Assets
0.61
Net Debt to EBITDA
-0.06
Current Ratio
0.51
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-37.41
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1260723
Debt to Market Cap
0.54

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cingulate Inc. Dividends
Year Dividends Growth

Cingulate Inc. Profile

About Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CEO
Dr. Shane J. Schaffer Pharm.D.
Employee
15
Address
1901 West 47th Place
Kansas City, 66205

Cingulate Inc. Executives & BODs

Cingulate Inc. Executives & BODs
# Name Age
1 Dr. Matthew N. Brams M.D.
Executive Vice President & Chief Medical Officer
70
2 Dr. Shane J. Schaffer Pharm.D., PharmD
Chief Executive Officer, Principal Financial Officer & Chairman of the Board
70
3 Dr. Laurie A. Myers M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
70
4 Ms. Jennifer L. Callahan CPA
Chief Financial Officer, Senior Vice President & Corporate Controller
70
5 Dr. Raul R. Silva M.D.
Executive Vice President & Chief Science Officer
70
6 Thomas Dalton
Head of Investor & Public Relations
70

Cingulate Inc. Competitors